Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Timeline

Start

2026-04-15

Primary completion

2028-05

Completion

2029-03

Drugs

Indications